Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -2,9 +2,9 @@
2	2	(((
3	3	(% class="container" %)
4	4	(((
5		-= //A new tridimensional diagnostic framework for CNS diseases// =
	5	+= //A new tridimensional diagnostic framework for complex CNS diseases// =
6	6
7		-This project is focused on developing a novel nosological and diagnostic framework for CNS diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
	7	+This project is focused on developing a novel nosological and diagnostic framework for complex CNS diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
8	8	We aim to create a structured, interpretable, and scalable diagnostic tool.
9	9	)))
10	10	)))
...	...	@@ -18,38 +18,46 @@
18	18	= **Overview** =
19	19
20	20
21		-The classification and diagnosis of **central nervous system (CNS) diseases** have long been constrained by **traditional phenotype-based approaches**, which often fail to capture the **complex pathophysiological mechanisms, molecular biomarkers, and neuroanatomical changes** that drive disease progression. **Neurodegenerative and psychiatric disorders**, for example, exhibit significant **clinical overlap, co-pathology, and heterogeneity**, making current diagnostic models insufficient.
	21	+The classification and diagnosis of central nervous system (CNS) diseases have long been constrained by traditional, phenotype-based approaches that often fail to capture the complex interplay of pathophysiological mechanisms, molecular biomarkers, and neuroanatomical changes. Neurodiagnoses redefines this landscape by integrating advanced AI with multi-modal data—including genetics, neuroimaging, biomarkers, and digital health records—to create a more precise, scalable, and data-driven diagnostic system.
22	22
23		-This project proposes a **new diagnostic framework**—one that **shifts from symptom-based classifications** to an **etiology-driven, tridimensional system**. By integrating **genetics, proteomics, neuroimaging, computational modeling, and AI-powered annotations**, this approach aims to provide a **more precise, scalable, and biologically grounded method for diagnosing and managing CNS diseases**.
	23	+In addition to these clinical diagnostic approaches, Neurodiagnoses has expanded into a research-oriented platform through the integration of **CNS Digital Twins**. This cutting-edge concept involves creating a personalized digital replica of a patient’s CNS by incorporating multi-omics data (proteomics, genomics, lipidomics, transcriptomics), various neuroimaging modalities, and digital health information. These digital twins enable simulations of disease progression, support the discovery of novel biomarkers, and help identify new therapeutic targets.
24	24
25		-The **AI-powered annotation system** plays a critical role by **structuring, interpreting, and tracking multi-modal data**, ensuring **real-time disease progression analysis, clinician decision support, and personalized treatment pathways**.
	25	+On this page, you will find:
26	26
27		-=== **Project Aim** ===
	27	+* Detailed descriptions of both the clinical diagnostic tools and the research framework.
	28	+* Access to our AI models, data processing pipelines, and digital twin simulations.
	29	+* Collaborative resources for researchers, clinicians, and AI developers.
	30	+* Guidelines and instructions on how to contribute to and expand the project.
28	28
29		-The project aims to develop a **tridimensional diagnostic framework** with an **AI-powered annotation system**, integrating **etiology, molecular biomarkers, and neuroanatomoclinical correlations** for **precise, standardized, and scalable CNS disease diagnostics**.
30	30
31		-The //Tridimensional Diagnostic Framework// redefines CNS diseases can be classified and diagnosed by focusing on:
	33	+== **The role of AI-powered annotation** ==
32	32
33		-* **Axis 1**: Etiology (genetic or other causes of diseases).
34		-* **Axis 2**: Molecular Markers (biomarkers).
35		-* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
	35	+To enhance standardization, interpretability, and clinical application, the framework integrates an AI-powered annotation system, which:
36	36
37		-This methodology enables:
	37	+* Assign structured metadata tags to diagnostic features.
	38	+* Provides real-time contextual explanations for AI-based classifications.
	39	+* Tracks longitudinal disease progression using timestamped AI annotations.
	40	+* Improves AI model transparency through interpretability tools (e.g., SHAP analysis).
	41	+* Facilitates decision-making for clinicians by linking annotations to standardized biomedical ontologies (SNOMED, HPO).
38	38
39		-* Greater precision in diagnosis.
40		-* Integration of incomplete datasets using AI-driven probabilistic modeling.
41		-* Stratification of patients for personalized treatment.
	43	+Neurodiagnoses provides two complementary AI-driven diagnostic approaches:
42	42
43		-== **The Role of AI-Powered Annotation** ==
	45	+1. Traditional Probabilistic Diagnosis
44	44
45		-To enhance **standardization, interpretability, and clinical application**, the framework integrates **an AI-powered annotation system**, which:
	47	+* AI provides multiple possible diagnoses, each assigned a probability percentage based on biomarker, imaging, and clinical data.
	48	+* Useful for differential diagnosis and treatment decision-making.
46	46
47		-* **Assigns structured metadata tags** to diagnostic features.
48		-* **Provides real-time contextual explanations** for AI-based classifications.
49		-* **Tracks longitudinal disease progression** using timestamped AI annotations.
50		-* **Improves AI model transparency** through interpretability tools (e.g., SHAP analysis).
51		-* **Facilitates decision-making for clinicians** by linking annotations to standardized biomedical ontologies (SNOMED, HPO).
	50	+2. Tridimensional Diagnosis
52	52
	52	+* Diagnoses are structured based on:
	53	+(1) Etiology (genetic, autoimmune, metabolic, infectious)
	54	+(2) Molecular Biomarkers (amyloid-beta, tau, inflammatory markers, EEG patterns)
	55	+(3) Neuroanatomoclinical Correlations (brain atrophy, connectivity alterations)
	56	+* This approach enables precise disease subtyping and biologically meaningful classification, particularly useful for tracking progression over time.
	57	+
	58	+Both systems will be offered for every patient case, allowing clinicians to compare AI-generated probabilistic diagnosis with a structured tridimensional classification.
	59	+
	60	+
53	53	== **The case of neurodegenerative diseases** ==
54	54
55	55	There have been described these 3 diagnostic axes:
...	...	@@ -62,6 +62,8 @@
62	62	* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers.
63	63	* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression.
64	64	* //Tests//: Genetic testing, lifestyle, and cardiovascular screening.
	73	+
	74	+
65	65	)))
66	66	* (((
67	67	**Axis 2: Molecular Markers**
...	...	@@ -69,6 +69,8 @@
69	69	* //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression.
70	70	* //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology.
71	71	* //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET).
	82	+
	83	+
72	72	)))
73	73	* (((
74	74	**Axis 3: Neuroanatomoclinical**
...	...	@@ -96,10 +96,13 @@
96	96	* Develop interpretable AI models for diagnosis and progression tracking.
97	97	* Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
98	98	* Foster collaboration among neuroscientists, AI researchers, and clinicians.
	111	+* Provide a dual diagnostic system:
	112	+** Probabilistic Diagnosis – AI assigns multiple traditional possible diagnoses with probability percentages.
	113	+** Tridimensional Diagnosis – AI structures diagnoses based on etiology, biomarkers, and neuroanatomical correlations.
99	99
100	100	== Who has access? ==
101	101
102		-We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
	117	+We welcome contributions from the global community. Join us as we transform CNS diagnostics and drive precision medicine forward through a collaborative, open-source approach. Let’s build the future of neurological diagnostics together!
103	103	)))
104	104
105	105